We verified that this result was observed for postmenopausal breast cancers (n = 116, HRQ4vs.Q1 = 0.50 (0.26–0.97), P-trend = 0.03), ductal breast cancers (n = 119, HRQ4vs.Q1 = 0.42 (0.21–0.83), P-trend = 0.02), ER+ (n = 113, HRQ4vs.Q1 = 0.37 (0.18–0.76), P-trend = 0.02) and PR+ (n = 86, HRQ4vs.Q1 = 0.36 (0.16–0.81), P-trend = 0.046) breast cancers (data not tabulated). This evidence concerns the gene ESR1 and breast carcinoma.